Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Kasama, S. et al.

Shu Kasama, Takuji Toyama, Hiroyuki Sumino, Hisao Kumakura, Yoshiaki Takayama, Kazutomo Minami, Shuichi Ichikawa, Naoya Matsumoto, Yuichi Sato, Masahiko Kurabayashi,

Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction.

Objective To evaluate the effects of spironolactone on cardiac sympathetic nerve activity (CSNA) and left ventricular (LV) remodelling in patients with ST-segment elevation myocardial infarction (STEMI). Design Single-centre, prospective, randomised evaluation study. Setting Patients with a first STEMI and single-vessel disease undergoing primary coronary angioplasty. Patients Sixty patients randomly assigned to two groups before angioplasty. Interventions Patients were randomly assigned to receive or not the spironolactone before primary coronary angioplasty. Main outcome The extent score (ES) was determined by use of (99m)Tc-pyrophosphate scintigraphy to evaluate the area of initial myocardial damage 3-5&emsp14;days after primary angioplasty. The LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV) and LV ejection fraction were determined by echocardiography, and plasma procollagen type III aminoterminal peptide (PIIINP) was measured before and 3&emsp14;weeks after treatments. The delayed heart/mediastinum count (H/M) ratio, delayed total defect score (TDS) and washout rate (WR) were determined from (123)I-meta-iodobenzylguanidine scintigraphy after 3&emsp14;weeks. Results After primary angioplasty, age, gender, risk factors, culprit coronary artery, peak serum creatine kinase concentration, recanalisation time and ES were similar in the two groups. However, in the spironolactone group, the TDS and WR were significantly lower (TDS: mean (SD) 22.5 (8.0) vs 29.5 (10.1), p<0.005, WR: 30.5 (8.7)% vs 40.0 (10.9)%, p<0.001) and the H/M ratio was significantly higher (2.18 (0.37) vs 1.96 (0.30), p<0.05) than in the non-spironolactone group. Moreover, significant correlations were found between the degree of change in PIIINP concentration and change in LVEDV (r=0.559, p=0.001), or LVESV (r=0.546, p=0.002) in the spironolactone group. Conclusion Administration of spironolactone improves CSNA and prevents LV remodelling in patients with a first STEMI.[1]

References

Effects of spironolactone on cardiac sympathetic nerve activity and left ventricular remodelling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction. Kasama, S., Toyama, T., Sumino, H., Kumakura, H., Takayama, Y., Minami, K., Ichikawa, S., Matsumoto, N., Sato, Y., Kurabayashi, M. Heart (2011) [Pubmed]

Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.